Fig. 7
From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
Mode-of-action of EnanDIMĀ® molecules: Differential activation of secondary cells. Variation of sequences and thus secondary conformation have an influence on ā unspecific DNA-uptake by TLR9-positive cells, ā” differential uptake into the respective (early or late) endosomes resulting in either IRF7 or NF-kappaB activation followed by induction of specific cytokine pattern and surface marker expression resulting in differential activation of (TLR9-negative) cell subpopulations, and ā¢ specific binding to the TLR9 and thus strength of the response and subsequent thresholds for cell activation (which may differ between cell types)